Points for discussion

• When should you start to consider switching to GMP-grade ancillary materials? 
• Why use preclinical grade reagents for preclinical research instead of RUO reagents?
• Which quality attributes are relevant for preclinical research? How to qualify ancillary materials and assess their quality and economic risks?

Agenda

8:00am Panel 

8:50am Q&A

Speakers: 

Tess Kitchener, Vice President, BaseCamp Business Development, Elevatebio

Bernd Leistler, Vice President Production, Sartorius CellGenix 

Isaac Zentner, Associate Director, Process Development, Carisma Therapeutics

Stefano Baila, Managing Director, Eurofins

Lili Belcastro, Senior Principal Scientist, Cell and Gene Therapy Raw Materials, Bristol Myers Squibb